Armata Pharmaceuticals, Inc. Common Stock (ARMP) Stock Price

ARMPStock

$5.56+92.91%52W

Market Cap$206.73M

P/E—

PEG Ratio—

Div yield—

Beta1.39

ARMP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-47.34%

Price vs S&P 500 (4W)6.25%

VGM Score48.66

Book Value / Share (Quarterly)$0.53

P/TBV (Annual)1.74x

Revenue Growth (3Y)-3.81%

Cash Flow / Share (Quarterly)$-0.67

Price vs S&P 500 (YTD)-29.63%

Net Profit Margin (TTM)-5432.80%

EPS (TTM)$-7.76

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-7.76

Revenue Growth (5Y)43.00%

EPS (Annual)$-4.80

ROI (Annual)-102.33%

Net Profit Margin (5Y Avg)-1324.46%

Cash / Share (Quarterly)$0.13

Revenue Growth QoQ (YoY)60.69%

ROA (Last FY)-226.06%

Revenue Growth TTM (YoY)10.70%

EBITD / Share (TTM)$-0.98

ROE (5Y Avg)-117.52%

Operating Margin (TTM)-715.65%

Cash Flow / Share (Annual)$-0.72

P/B Ratio9.23x

P/B Ratio (Quarterly)2.16x

Net Income / Employee (Annual)$-2,849,200

EV / Revenue (TTM)98.88x

Net Interest Coverage (TTM)-0.27x

ROA (TTM)-356.62%

EPS Incl Extra (Annual)$-4.80

Current Ratio (Annual)1.19x

Quick Ratio (Quarterly)0.52x

3-Month Avg Trading Volume0.13M

52-Week Price Return92.91%

Revenue / Employee (TTM)$85,300

Tangible BV / Share (Quarterly)$0.24

P/S Ratio (Annual)35.93x

Asset Turnover (Annual)0.06x

52-Week High$16.34

Operating Margin (5Y Avg)-740.17%

EPS Excl Extra (Annual)$-4.80

CapEx CAGR (5Y)-7.95%

Tangible BV CAGR (5Y)56.05%

26-Week Price Return-36.09%

Quick Ratio (Annual)1.02x

13-Week Price Return-37.18%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.64x

Enterprise Value$514.36M

Revenue / Share Growth (5Y)22.08%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-38.52%

Revenue / Employee (Annual)$80,400

Pretax Margin (Annual)-3544.03%

Cash / Share (Annual)$0.24

3-Month Return Std Dev108.01%

Net Income / Employee (TTM)$-4,633,000

ROE (Last FY)-102.33%

Net Interest Coverage (Annual)-0.15x

EPS Basic Excl Extra (Annual)$-4.80

Receivables Turnover (TTM)4.70x

Total Debt / Equity (Quarterly)1.38x

EPS Incl Extra (TTM)$-7.76

Receivables Turnover (Annual)4.17x

ROI (TTM)-81.23%

P/S Ratio (TTM)33.87x

Pretax Margin (5Y Avg)-1324.46%

Revenue / Share (Annual)$0.14

Tangible BV / Share (Annual)$0.71

Price vs S&P 500 (52W)74.60%

Year-to-Date Return-17.68%

5-Day Price Return13.38%

EPS Normalized (Annual)$-4.80

ROA (5Y Avg)-77.97%

Net Profit Margin (Annual)-3544.03%

Month-to-Date Return13.88%

Cash Flow / Share (TTM)$-1.62

EBITD / Share (Annual)$-0.97

Operating Margin (Annual)-747.02%

LT Debt / Equity (Annual)0.38x

ROI (5Y Avg)-116.66%

LT Debt / Equity (Quarterly)0.38x

EPS Basic Excl Extra (TTM)$-7.76

P/TBV (Quarterly)4.68x

P/B Ratio (Annual)1.24x

Pretax Margin (TTM)-5432.80%

Book Value / Share (Annual)$1.00

Price vs S&P 500 (13W)-39.97%

Beta1.39x

Revenue / Share (TTM)$0.14

ROE (TTM)-120.00%

52-Week Low$2.40

vGradeD

gGradeB

mGradeC

vgmGradeC

ARMP Earnings Surprise History

Q2 25-0.29est. -0.39

Q3 25-0.33est. -0.42

Q4 25-0.36est. -0.19

Q1 26-3.16est. -0.38

Q2 261.20est. -0.45

ARMP Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARMPArmata Pharmaceuticals, Inc. Common Stock	D	B	C	$5.56
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals develops bacteriophage therapeutics to treat antibiotic-resistant bacterial infections using proprietary phage-based technology. The company has clinical-stage candidates targeting major pathogens including Pseudomonas aeruginosa and Staphylococcus aureus, with additional programs in development. Armata is also collaborating with Merck on synthetic phage candidates for an undisclosed infectious disease target, diversifying its pipeline across difficult-to-treat infections.